Loading data for PSNL — first visit, this takes a few seconds.

Personalis, Inc. (PSNL)

NasdaqGM: PSNL · Precio en tiempo real · USD

16.78

-0.29 (-1.70%)

Al cierre: Aug 31, 2026, 3:59 PM

16.50

-1.67%

Premercado: 6:09 AM

Alerta

Alert

El precio, las cifras principales y las últimas noticias, en un solo sitio.

-1.70% (1D)

Precio de compra	9.7
Capitalización de mercado	1.79B
Ingresos (TTM)	69.7M
Beneficio neto (TTM)	-107M
	2.29
	-1.07
	n/a
	-17.82
P/B (TTM)	7.59
P/S (TTM)	25.71
Fecha de resultados	Nov 3, 2026

Precio de venta	17.35
Volumen	2,801,740
Volumen medio (20D)	4,182,188
Abierto	16.97
Anterior Cerrar	17.07
Rango del día	16.62 - 17.24
Rango de 52 semanas	4.67 - 18.89
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de PSNL

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics t...

[Leer más]

Industria Diagnostics & Research

Sector Healthcare

IPO Fecha Jun 20, 2019

Empleados 259

Bolsa de Valores NasdaqGM

Símbolo bursátil PSNL

Sitio web https://www.personalis.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Personalis fueron 69.65M, una disminución de -17.69% en comparación con 84.61M del año anterior. Las ganancias fueron -81.27M, una disminución de -0.02%.

Estados financieros

Sorpresa de resultados

Personalis ha publicado sus resultados trimestrales en Aug 4, 2026:

Ingresos de $22.36M falla las estimaciones por $0, con 29.96% Crecimiento interanual.
EPS de -0.3 falla las estimaciones por -0.02, con -30.43% Disminución interanual.

Próxima publicación de resultados

Está previsto que Personalis, Inc. publique sus resultados el Nov 3, 2026, durante el horario de mercado.
Los analistas proyectan ingresos de ... Actualizar

Por qué se movió el precio

Noticias

4 días hace · Insider Monkey

Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?

Tempus AI, Inc. (NASDAQ:TEM) rallied following a melanoma breakthrough reported by Moderna and Merck. The companies said their Phase 3 INTerpath-001 trial met its recurrence-free survival endpoint for...

5 días hace · Barchart

Personalis Stock Is Up 250% in the Past Year. It Needs to Turn a Profit Next.

Personalis (PSNL) has demonstrated exceptional momentum, gaining nearly 250% over the past year. Shares recently set a new 3-year high. PSNL stock maintains a 100% “Buy” technical opinion from Barchar...

1 semana hace · MT Newswires

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks decreased late Monday afternoon, with the NYSE Healthcare Index and the State Stre

1 semana hace · Simply Wall St.

Tempus AI (TEM) Stock Looks Fully Valued After Its 55% Jump

Tempus AI stock has surged over the past month, yet the valuation picture is split. The Discounted Cash Flow (DCF) intrinsic value estimate points to shares trading at a roughly 33.1% discount, while ...

1 semana hace · Simply Wall St.

Tempus AI (TEM) Is Up 39.5% After mRNA Melanoma Trial Win And Personalis Deal - What's Changed

In recent days, investors have reacted to phase 3 INTerpath-001 trial results showing a customized mRNA-based melanoma treatment improved recurrence-free survival, while also focusing on Tempus AI’s p...

Página 1 de 2

Personalis, Inc. (PSNL)